ImmunoBrain's Anti-PD-L1 Antibody IBC-Ab002 Shows Early Biomarker Signal in Phase 1b Alzheimer's Trial, Published in Nature Medicine
核心洞察
ImmunoBrain (搜索)'s Phase 1b trial of IBC-Ab002, an anti-PD-L1 (搜索) antibody, met its primary safety endpoint and showed encouraging reductions in neuronal and synaptic damage biomarkers in early Alzheimer's disease (搜索).
Most patients receiving the highest dose demonstrated reductions in cerebrospinal fluid biomarkers including neurogranin (搜索), total Tau (搜索), and pTau181 (搜索) over the 48-week trial.
The findings, published in Nature Medicine and presented at AAIC 2026, represent the first clinical signal for checkpoint immunotherapy in Alzheimer's disease (搜索).
ImmunoBrain (搜索), a clinical-stage biopharmaceutical company, announced that its investigational anti-PD-L1 (搜索) antibody IBC-Ab002 has demonstrated an early positive signal in a Phase 1b clinical trial for early Alzheimer's disease (搜索). The results, published in Nature Medicine and presented as a late-breaking abstract at the Alzheimer's Association International Conference (AAIC) 2026, mark the first clinical evidence supporting checkpoint immunotherapy in a neurodegenerative disease setting.
The publication, titled "Immunotherapy with a short-lived anti-PD-L1 (搜索) antibody in Alzheimer's disease (搜索): a phase 1b, randomized, double-blind trial," details findings from the IBC-01-01 study conducted across 11 centers in the United Kingdom, Israel, and the Netherlands.
Safety and Biomarker Findings
The trial met its primary endpoint of safety, with IBC-Ab002 shown to be well tolerated at all doses tested. Beyond safety, the study generated encouraging fluid biomarker data. At the end of the 48-week treatment period, most patients receiving the highest dose exhibited reductions across a panel of neuronal and synaptic biomarkers in cerebrospinal fluid, including neurogranin (搜索), total Tau (搜索), and pTau181 (搜索). The treatment was also shown to achieve target engagement.
A Peripheral-Immune Approach
IBC-Ab002 is a fully human, Fc-modified anti-PD-L1 (搜索) monoclonal antibody designed specifically for neurodegenerative diseases. Unlike antibody programs that directly target pathological proteins or cells in the brain, ImmunoBrain (搜索)'s platform activates the peripheral immune system to support brain protection and repair. The therapeutic benefit of IBC-Ab002 is Cmax-dependent rather than driven by continuous exposure, and its short half-life combined with intermittent administration is intended to minimize immunological risk during chronic dosing without compromising efficacy.
The approach builds on more than 25 years of pioneering research by Professor Michal Schwartz at the Weizmann Institute of Science, whose work challenged the long-standing dogma that the brain is isolated from the immune system and uncovered the critical role of the immune system in maintaining brain health and promoting brain repair.
"Our approach, the first of its kind, aims to restore the immune system's ability to protect and repair the brain," said Professor Schwartz. "It is deeply rewarding to see how curiosity-driven research that challenged the long-standing dogma that the brain is isolated from the immune system has led to a paradigm shift in our understanding of neurodegenerative diseases. By targeting a common repair pathway rather than the primary cause of the disease, this work has now translated into encouraging clinical results."
Next Steps
The Phase 1b trial (NCT05551741) was supported in part by grants from the National Institute on Aging (NIA) under Award Number R01AG071810 and the Alzheimer's Association. ImmunoBrain (搜索) is currently designing the protocol for the next phase of clinical development. IBC-Ab002 remains investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.